The dark side
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I just read that whole novel of a book that came with the voting information. Trying to read through the lines a bit. I think the obvious benefits are there the market share, patients, extra revenue, more prescribing doctors ect ect . On top of that I believe a very large bonus of this deal is that it removes and easy entry point away and out of the market for anyone large to step into the space. MT was by far the best entry for pharma tobacco alcohol companies. APH is the only company left that makes any sense to enter through. The platform has to be big enough and be able to expand fast. I don't see anyone entering through those small 10,000 sq foot companies. There no value there. This pushed the prices up and removed an easy entry for any competition to enter. Just a thought after reading the giant book of material.
There's an option on the voting website called vote with management. which basically lets the management use your shares to vote whichever way they see fit. you should at least use that option so your shares are not wasted. It would take you less than 30 secs
Also received my materials Friday. Voted both Mettrum and Canopy shares "For" . Used proxyvote and investorvote websites. Easy to do. No reason not to vote. Here's to 40% of the market and a dominant position moving forward. GL
A True Gem:
Every once and a while, a true gem emerges in the market. Whether it’s an innovative new product, a technological or medical breakthrough, or even a merger of equals, these gems offer investors lucrative returns and become almost legendary.
Last year, Canopy Growth Corp. (TSX:CGC) was on track to join that elite club as the small Smith Falls–based company with a market cap of over $2 billion and revenue of just $8.5 million ignited a fire in a new and potentially lucrative segment of the market.
While more conservative investors may see 2016 as an anomaly and dismiss significant growth, analysts agree for the most part that Canopy represents a unique position in the market for a host of reasons.
Market potential
Sentiment around legalized marijuana is changing around the world. Over the past year, we’ve seen many parts of the world put legislation into effect that allows cannabis for medicinal purposes, including in the U.S. general election this past fall in which several states included a legalization motion on the ballot. Over half of U.S. states now allow medical marijuana, and more than half a dozen states have adopted (or will shortly) recreational marijuana laws for residents over the age of 21.
As more markets open to the possibility of legalized marijuana, the potential market cap continues to grow. Some experts now peg that market size will balloon to US$50 billion over the next decade with double-digit growth every year until then. Here in Canada, those growth figures are even more staggering with one in six Canadians estimated to consume legal marijuana annually over the next few years.
Growing momentum
One of the factors that helped propel Canopy’s meteoric rise last year was a series of masterstroke deals that helped the company gain both international exposure as well as strengthen Canopy’s position here at home.
Specifically, the acquisition of German distributor Medcann opened Canopy to the German market well ahead of the competition, and the acquisition of Toronto-based Mettrum Health Corp. that followed directly thereafter was a turning point for Canopy.
The Medcann deal is primarily an offensive one for growth, whereas the Mettrum deal can be seen more as a defensive one to rein in costs and eliminate a competitor. In any respect, Canopy now has an international outlet and will have possession of two health Canada growth licenses through the Mettrum deal.
Is Canopy a good investment?
Some experts view investing in the marijuana market at this point to be like investing in alcoholic beverages shortly before the end of Prohibition. The market is there, the demand is there, and the supply is steadily growing (pun intended). All that is needed is for legislators around the world to enact the laws to make it legal.
Canopy is strategically situated to be on the forefront of this emerging industry. While there could be a few surges and drops in the coming months, over the long term, Canopy remains an interesting investment option.
The Bedrocan bash is working like a charm and keeping our head above water.
I've been nibbling at both stocks but saw someone eat up 50,000 k Mettrum shares today at 6.75. Over half MT s usually daily volume. Might be just a large retail investor though.
The stock seems to be trading different today slower with smaller lots in the hundreds and when the fake asks get put up there's no selling into the bid. Easier on my heart, would this be the algorithms are gone? I think we're alone now.
Today's Friday the 13th, the only thing scarier than that is Bedrocan's sales.
Thank you for this! Germany is looking good for sure. I think this is where the next 2 billion in or market cap comes from ;) Glad to see Germany is so liberal towards cannabis.
I'm not too sure why they'd buy them other than to take away the stream of patients from other LPS. If enough doctors are using these stores you also take away doctors from other LPS. Like D the other poster was saying they don't look like storefronts being inside multilevel buildings. Who knows. I think Aph just bought up some as well earlier this year and Canopy bought up some in 2015. Smart to get this deal done before the merger, Canopy has done too many deals of late with their own stock. As for how profitable storefronts are read this, they are very profitable but not apply store worthy
https://www.leafly.com/news/politics/cannabis-retailers-make-more-money-per-square-foot-than-whole-foo
Very nice read the future is bright and just a few short months away. Globe and Mail sector outlook.
https://www.google.ca/search?q=http%3A%2F%2Fwww.theglobeandmail.com%2Fglobe-investor%2Finvestment-ideas%2Fresearch-reports%2Farticle33564366.ece%2FBINARY%2FMARIJUANA-2017-1-10-Globe.pdf&client=ms-android-samsung&sourceid=chrome-mobile&ie=UTF-8
Canopy Growth Corp. (CGC-T) – Buy recommendation, $14.50 target price. In our view, Canopy is
the leader in the sector. The company has the most market share, revenue, and capacity among all
licensed producers (LPs). Canopy’s strategy is to play to win the long game, and incorporates:
dominating market share and production capacity; creating and/or offering multiple consumer
facing brands; focusing on higher value products as permitted by government regulations; and
pursuing international opportunities where federally legal. The company’s goal is to invest now to
further its brand awareness so that the first time buyer gravitates towards its products come Day 1 of
legalization.
Potential Catalysts In Q1/FY17
? Inclusion In The S&P/TSX Composite Index. Based on our read of the
criteria, we believe there is a very good chance that Canopy is
added to the S&P/TSX Composite Index during its Q1/FY17
rebalancing. In terms of key dates, we anticipate that the
announcement listing index changes will be released between March
1 and March 14, 2017, with them taking effect on March 17, 2017. We
expect that this would create natural demand for Canopy’s shares
specifically, and may help to further ‘legitimize’ the industry as a
whole.
Do you pay them a fee? To get your prescription? Or ongoing fees?
Why do you think these producers are buying up these clinics? Just to ensure all the patients come their way? Or possible store from clinics coming?
Yes it's early agreed, their market cap is only 10 million it's temping. But you're right it will be years and a lot of Cash to get through the trails.
http://www.proactiveinvestors.com.au/companies/news/169926/zelda-therapeutics-to-work-with-a-leading-medical-research-institute-169926.html
Canopy should just swallow these guys up.
The deal as I remember it is: Canopy would own 15% of the new company with the ability to pick up another 5% at the same evaluation. Their share percentage cannot be diluted. So if the issue more shares they'll still retain 15% of the company? Going from memory though. All of this for expertise which is valuable to AusCann and a great deal for us.
Buy/Sell Adviser
Canopy Growth is a diversified cannabis company engaged in growing and distributing medical marijuana products to patients across Canada. Mettrum Health Corp. is also a producer of medical cannabis and cannabis products. PI Financial analysts give both healthcare stocks a ‘buy’ with ‘speculative risk’ rating.
Licensed medical marijuana producer Canopy Growth Corp. (TSX—CGC) reached new highs, including sales exceeding one tonne, yet again during the second quarter of its 2017 fiscal year.
The healthcare stock reported quarterly (period ended Sept. 30, 2016) revenue of $8.5 million, up 245 per cent from the same period in fiscal 2016. Canopy sold a total of 1,169 kilograms (or 1.169 metric tonnes) of marijuana during the second fiscal quarter, and harvested 1,711 kilograms as well.
These exceptional results generally paralleled PI Financial analysts Jason Zandberg’s and Devin Schilling’s expectations. The analysts had forecast $8.5 million in revenue and marijuana sales of 1,210 kilograms.
According to the analysts, fiscal second-quarter operating costs rose 44 per cent to $7.9 million compared to fiscal 2017 first-quarter costs of $5.5 million. They say this was due to higher costs in sales and marketing (up $600,000), research and development (up $100,000), acquisitions (also up $600,000), and general and administrative costs (which rose $1.2 million).
Messrs. Zandberg and Schilling nevertheless note that this healthcare stock has kept up with the analysts’ aggressive growth expectations. Its average cost of production should decline in future quarters since its Tweed Farms greenhouse operations are in full production, they add.
The analysts have slightly raised their revenue growth rate expectation for the next couple of fiscal years. Thus, their revenue forecasts also increase.
They predict revenue of $37.9 million for fiscal 2017, $100,000 more than before, and $84.6 million for the following fiscal year, previously $76 million.
Citing upcoming legislation legalizing recreational marijuana in Canada, and the growing acceptance of cannabis in the United States, the analysts say they believe there is some upside to their market forecast of $4.6 billion in 2019.
The analysts say they expect Canopy to be among the market leaders and raise their 12-month target price for the grower to $12 a share, previously $7. They have maintained a ‘buy’ recommendation and ‘speculative’ risk rating.
Canopy management reported that Tweed Farms yielded about 750 grams of marijuana per plant in the recent fiscal quarter. The analysts estimate the inventory is worth $40 million to $50 million after the crop’s harvest.
“The large inventory is a competitive advantage for CGC given industry supply across the medical marijuana sector is currently very tight with some competitors unable to fulfil demand,” say Messrs. Zandberg and Schilling.
Medical cannabis production rising to meet demand
In an earlier July, 2016 research note, Messrs. Zandberg and Schilling had initiated coverage of another medical marijuana stock, Mettrum Health Corp. (TSXV—MT), with a ‘buy’ recommendation and a 12-month target price of $3.50 per share.
At the time the analysts said that Mettrum had developed strong relationships with physicians and clinics, and they started coverage of the healthcare stock due to the company’s growth potential. The company had a roster of 12,099 patients at the conclusion of June, second only to Canopy Growth’s 16,000-plus patients.
They noted that Mettrum had plenty of opportunities to grow more plants indoors using modular technology on 80 acres of zoned property.
Fast forwarding three months later, Messrs. Zandberg and Schilling reviewed Mettrum’s second quarter results for fiscal year 2017. They say that revenue was up to the tune of 180 per cent to $4.8 million. Earnings before interest, taxes, depreciation and amortization (EBITDA) came in at -$1.1 million versus -$2.1 million a year ago, and earnings per share came in at -$0.05 compared to -$0.06 in the year-earlier quarter.
“We had modelled revenue of $4.7 million in the second quarter and EBITDA of $500,000,” say the analysts. “Mettrum’s patient count at the end of the quarter was 15,330, slightly ahead of our expectation of 14,520 although patient count is becoming an unreliable data point as patients register with multiple licensed producers.”
During the quarter, Mettrum sold 480,000 grams of medical marijuana, which was less than the 524,000 that the analysts projected.
“Demand for product was strong during the quarter and Mettrum stated that it did require buying third-party product to satisfy that demand,” say the analysts. “Moving forward, we expect Mettrum to be able to satisfy demand through its own production as Bowmanville South expands.”
The analysts keep their ‘buy’ recommendation, with ‘speculative’ risk, and they boost their 12-month target price to $8 per share from $4.25 per share
Canopy Growth Corp (CGC.TO): Cowen and Company starts with outperform rating; price target $13
More analysts coming on board.
Thank you,
I'll be watching Germany close. Right now I'm happy to let Canopy make me a Germany investor as I think they'll be a very Germany company. The market there look very interesting. May be smart to get into something there before they vote on Jan 17 to let drs prescribe.
Make sure you do your DD. I don't know much about AusCann stock I've never even looked at it and I have no idea about the Australian stock market. I'd imagine if you plan to hold 3 years like Canopy they'll make you a lot of Cash. Also remember you already own 20% of AusCann through Canopy. I'm interested in the German market as well. I'd love to know more about the companies out there.
This is what I love about this company. They have the recreational market coming soon and longer term they have a chance to hit it big, very big on the pharma side. Bruce knew these guys were the ones before the headlines came out about Zelda and their formulation for shrinking tumors. He is miles ahead of this board I'd say at best we're 6 months behind what's going on at Canopy. This is significant and excites me more than the recreational market. If they developed and prove this to work in clinical trials. Canopy seems to have at least a relationship with Zelda by supplying them with cannabis. We may own a piece as well through AusCann. That would be some good DD, to find they connection between the three companies. This could make the recreational market look like a grain of salt in Canopy’s revenue one day. Not to mention owning a company that brings relief to Cancer patients and could possibly cure their tumors.
After a reasonably subdued start to life as a listed company Zelda Therapeutics Ltd (ASX: ZLD) certainly grabbed the attention of the market this morning.
The medicinal cannabis company’s shares are on fire today and are higher by a whopping 48% to 3.4 cents.
Today’s gain comes following the announcement of positive results from its proof of concept study into the anti-cancer effects of its tetrahydrocannabinol-rich medical cannabis formulation.
According to the release the research by world leading cannabis cancer researchers at Madrid’s Complutense University shows that the formulation is significantly more potent at reducing tumour growth than pure tetrahydrocannabinol.
Furthermore, the formulation is equally as potent as Lapatanib in reducing tumour growth. Chemotherapy drug Lapatanib is a tyrosine-kinase inhibitor of HER2 and EGFR. Both of these receptors are known to play an important role in breast cancer.
The research study was carried out in immune-deficient mice hosting tissue grafts of human breast cancer, HER2+ adenocarcinoma. The treatment was delivered orally to the mice and tumour volume was measured daily.
Whilst this is an exciting breakthrough, it is worth remembering that it will be some time before human trials commence. So it might be a little early to get over excited.
But overall I think medicinal cannabis has enormous potential and the high quality companies with strong management teams have a great chance of success. Whilst my preference is for the soon-to-be listed AusCann, there is room for both companies in this huge market in my opinion.
Not only do both AusCann and Zelda have close ties and shared expertise, but they are targeting different areas of the market as I explained recently.
This is the chit I'm talking about right here. Also my favorite original Nintendo game Zelda. You may have heard the name worldwide for finding a formulation for killing cancer cells!
http://www.perthnow.com.au/news/western-australia/researches-test-if-medical-cannabis-can-treat-pancreatic-cancer/news-story/1f1761371d37b2f0e39a41d8507d3646
Just some food for thought
Phillip Morris a company with a 150 billion dollar market cap... 150 billion. Has an EPS of 4.18. They have 1.5 billion outstanding shares. Per quarter they are earning 1.56 billion.
If Canopy had a 150 billion dollar market cap their share price would be $937 per share fully diluted.
Now what are the chances Canopy makes 1.5 billion a quarter?
The Canadian medical market we know is on track to be 1.5 billion in the next 2 years. Canopy controls 40% of that currently.
600,000,000+
The recreational market is estimated at 5-7 billion and is also expect within 2 years. Canopy has said they want 40% of this market but let's give them 10%
600,000,000 + 700,000,000
The German market which is twice the size of Canada opens this year for all medical users and is expected to be covered by health insurance. A 3 billion dollar market. What percent will Canopy have?? Right now there's only a few distributers there I'd say they can capture 25% lIke they did early in the Canadian market .
600,000,000 + 700,000,000 + 750,000,000 = 2.050 billion revenue. This is the start and is calculated from numbers that will happen in 2 years time 3-4 for Germany .
30 % margin is 615 million. 3.84 EPS and a price per share of $96.
Giving Canopy a market cap of 15 billion and making them 10% the company of Phillip Morris to start.
Australia and other countries that open up excluded. Germany may take longer to reach 3 billion I think they'll have faster growth due to health insurance. Every rec user is going to be signing up there for free cannabis. Other than that these are the data points we have currently. It also shows that recreational isn't everything. 700 million rec compared to 1.4 billion medical in the next few years. We'll also see medical open up first in new countries. I'm placing my bets on medical for my investment recreational is icing on the cake. They need to Grow and grow fast.
Phillip Morris EPS: A current EPS for fiscal year is observed at $4.18
One year price targets of $12-14.50 from analysts predicting 140-144 million in 2018. I think they double that easily. So $17 will be a good buy.
Think about it this way. Canopy spent 400 million on Mettrum who currently was directing 15% of all medical cannabis users toward their company. The medical sector is on track and confirmed by the globe and mail article with Cam Battley comments to be a 1.5 billion market in 2 years. That 15% will be worth 225,000,000 million per year in the not so distant future. I want to see the market grow to this size that the only thing I'm watching and it seems to be on track with 130,000 patients. If those estimates are correct and the market does reach that size so quickly the Mettrum deal will go down as a steal as the deal will pay for itself in 2 years not even taking into account the recreational market or other markets that open up. GL
Is THC actually selling at 4.20 or they have plans too? I heard that a long time ago and my thoughts were. They don't have a hope of doing that with an 11,000 sq foot Facility? Tweed had to raise their prices from $5 a gram to a higher price and their platform us something like 700,000 sq feet I believe. So good luck to THC biomedical I have a feeling the 4.20 price was a media gimmick.
They won't continue to buy from people like awesome sound. Would you go buy a bottle of wine from your neighbors who home brew or just go to the store and grab one. The only place I've seen people grabbing alcohol from neighborhood brewers was in papua new guinea. To think that's the state of Cannabis in Canada is sad. Onward into the future we now have PHD scientists making formulations for us that will cause different sensations love happy sleepy pain management euphoria ect.. who the hell wants to buy some bikers trash weed these days.
Legal weed growing as fast as cable TV and broadband Internet.
"The only consumer industry categories I've seen reach $5 billion in annual spending and then post anything like 25% compound annual growth in the next five years are cable television (19%) in the 1990s and the broadband internet (29%) in the 2000s," said Tom Adams, editor-in-chief of Arcview Market Research, in a statement.
https://flipboard.com/@flipboard/flip.it%2Fhl-SUj-the-legal-weed-market-is-growing-as-fas/f-ca41d31250%2Fbusinessinsider.com
I think it will hit new highs I have no idea how high though.
I've been working with machine learning check it out, it's the future no doubt. Also agree that there won't be many jobs soon. The Canadian Government has already talk about everyone receiving a living wage. They'll have to do that sooner or later in our life we'll see it. The Canadian liberals have it right they need to pay everyone a living wage. They had the wrong idea that it should only go to people making under poverty levels and it got rejected buy the working class big time. They need to pay everyone that wage no matter what your income and we'll see it pass with flying colors. We are a country on natural resources we're lucky. I logged on to say what a nice close today and got rapped up in this.
CGC starting to show signs of life. I like that close on the 50 day moving average.
Canopy's business seems to be growing fine with this huge problem of dispensaries. It can only get better. They can shut these places down I don't agree it's an impossible task. City bylaws ect look at Montreal they raided them the first day they opened. Back in my poor as s day I looked to open a hot dog vendor in Toronto. Those guys make between 80,000-100,000 dollars per year. And most only own the cart and the "licence to sell and some student sells the dogs. Do you know how hard it is to get a licence to sell hot dog .... hit dogs. There are so many restrictions on where these carts can be located it is almost impossible. I spent 6 months of my life trying to get a licence finally found a place that met the restrictions and it was on the outskirts of the city almost on a highway. My point is there are ways of restricting. As soon as they have restrictions in place they will enforce them believe me.
What you're talking about here is a business owner taking a huge risk of losing their business licence for saving a few dollars and using illegal product. If mom and pop shops are open to distribute they'll be making amazing money. They won't risk it unless they're really stupid. If this is how it plays out my goal if life until it happens will be to own one of these stores then sell it for a rediculous profit 5 years later. I might have to apologize to Bruce for wanting to kick him in the balls first for rising money so many times before he gives me any product.
Didn't they just raid a bunch of dispensaries in Montreal and 50 or so in Toronto. Sure they can keep opening but how will they every keep up when they have no excess to capital face prosecution fines and risk of incarceration.
I'd say to you where will the product come from if not from LP'S. Where's the other infrastructure to supply any cannabis for anyone to make money. They need the LP system to work if this is going to happen. Help me obi wan kenobi you're our only chance. Even if there's 200 little grows the demand isn't even close to filled. The government isn't going to tax this hard. What do you mean? I'm listening and interested to hear your opinion you see a flaw in the business plan or you're wishing to get this cheaper?
If I have a lineup of all the LP'S product in front of me and I've never heard of APH or their stock and I don't care about any of that why as a customer am I going to buy Aphria product? They have no answer to this question.garbage
Maybe there will be a limit on licences? I've had a gut feeling about this. When the government ended prohibition they capped the amount of licences created very large companies and murdered the black market. They couldn't compete on price or quality. Now years later they murder us with taxes on booze because there is no longer an underground booze network. History is repeating itself. That licence Canopy just bought may be extremely valuable. Bruce may know what he's doing. I've heard him talk about those companies that came out of prohibition in interviews before. After 3 years we have 30 licences, I don't believe thus is from lack of resources to get the paperwork done anymore. We might see a cap. If there is a cap how valuable are those 2 licences?
I don't understand this dispensary kick your on, why would you go around buying up expensive retail space at this point is not the way to go. The money is in developing products that people want and letting other people pay the rent and get your product on the shelf where ever they sell it doesn't matter. The government is not going to allow random cannabis to be sold that doesn't come from a regulated source. That is their whole point in doing this, they are going after those people good, bad, activist, anarchist, hibilly, hipster. When the laws are in place an illegal dispensary will not exist. Just like an illegal beer store does not exist. A lot of the tax dollars will go toward education programs of how and where to buy Cannabis. Most people will follow the law why wouldn't you. I know myself I have a certain distaste for the people who are criminally profiting when I pay very large taxes and have to follow regulations. There may be a generation of awesomesound people that still support some local grower but that will die of quickly. I've never met a weed dealer that I liked before. You usually are cursing their name wait in your car in a shady part of the city for some retard that might not even show up. Goodbye to that
On January 19, 2017, the German Parliament (Bundestag) will adopt a law that allows every doctor to simply prescribe cannabis beginning in March or April of 2017 with a so-called “narcotics prescription.”
http://www.marijuana.com/blog/news/2016/12/the-long-wait-for-cannabis-made-in-germany/?utm_content=buffera9df8&utm_medium=social&utm_source=twitter.com&utm_campaign=buffer
Wait till the banks start covering the space. People listen to those price targets. The analyst's covering the space now are conservative. Look up their reports and read them. Most are pricing only 40-60 million in rec sales 2018. If you think Canopy makes 100 million in medical which they will no doubt in my mind by 2018.
In a research update to clients today, Brown maintained his “Buy” rating on Canopy Growth, but raised his one-year price target to $13.50, implying a return of 35 per cent at the time of publication.
Brown thinks Canopy will generate Adjusted EBITDA of negative $3.40-million on revenue of $68.2-million in fiscal 2017. He expects these numbers will improve to positive EBITDA of $12.8-million on a topline of $141.8-million the following year.
I know Zandberg raise his price target to $13 something but I can find it and predicts 144 million similar to Brown
In a research update to clients today, Zandberg maintained his “Buy” rating and one-year price target of $12 on Canopy Growth Corp.
Zandberg believes Canopy will generate EBITDA of negative $5.0-million on revenue of $37.9-million in fiscal 2017. He expects these numbers will improve to EBITDA of $15.7-million on a topline of $84.5-million the following year
This one you have to pay to read but I read it free from someone who posted it. Do some searching you'll find it.
Canopy Growth (CGC-T) "new buy", price target of $14.50 at Beacon Securities
Why Canopy growth isn't overvalued and no Bruce didn't pay too much for MT: Yoda's never ending rant. For new investors and old ones if you, want to hear it again.
Take it as you will everyone has an opinion. 5% of the lowest estimated market would give CGC over 250-300 million in sales.
Analyst price targets of $12-14.50 per share are pricing in CGC only selling 140 million in 2018-2019.
CGC combined with Mettrum is currently today selling 15 million per quarter or 60 million annually.
Canopy has been growing just by itself 1.5-2 million revenue added every quarter for the past 2 quarters. There's no reason that doesn't continue.
Plus whatever Mettrum brings in growth, as well as GERMAN sales showing up this quarter.
Bedrocan price hike and new shipping charges also show up this quarter.
I know that cash flow positive was written into the Canopys management bonus for this year so if they didn't hit it this quarter they're out of luck.
Taking into account Mettrum Canopy should be selling 70-75 million next year. Closing in on 100 million plus the next in the medical market.
So 2018 as the company stands today not taking into account German sales or other deals that may add revenue, is reaching 100 million by 2018 in medical sales.
This doesn't need anything to happen no government no legal rec sales ect , it is happening right now.
Now factor in the recreational market. I use 5% because maybe an early market will be much smaller than expected, or maybe not who knows.
So 5% is adding 250-300 million in sales on top of the medical. Canopy could be looking at selling almost half a billion in the next 2-3 years. Call me crazy,
You can put whatever multiple / Ebitda / EPS whatever you want to do with it. You can even use common sense and think a company selling half of it's market a year will not be trading so low.
I've always valued the company at 100 million medical and 200 million recreational even more conservative. I don't see what is going to stop Canopy from hitting those numbers. It's not going to be production, they will have doubled by mid 2017 and I'm guessing that's just the start. Who is left to compete? APH? The company that ripped off the government and veterans? The other companies are mostly garbage imo. I've tried multiple times to spread my money out a bit, I bought a little MT. It was the only other company with any kind of brand awareness.
I think when the market opens and Canopy hits those numbers , we'll all be surprised and those screaming overvalued will have to take a 2nd look at the company and not just play the stock.
Playing the stock is all fine nothing wrong with riding waves. Everyone holding on will make out just fine too. Even in Medical sales I think this company can sustain a billion market cap in a few years.
GL may the force be with you
I believe tweed has said if you order before 2pm the order will be shipped the same day. Maybe that has changed?